Nonhypoglycemic Effects of Thiazolidinediones

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Annals of Internal Medicine

• Publication date

  2001-01-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.7326/0003-4819-134-1-200101020-00014PMID 11187421
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Fulminant Hepatitis

  2010cited by this paper
• Peroxisome proliferator-activated receptors (PPARs) and their implications in diseases

  2000cited by this paper
• Expression and Function of PPARγ in Rat and Human Vascular Smooth Muscle Cells

  2000cited by this paper
• Expression and Function of PPARg in Rat and Human Vascular Smooth Muscle Cells

  2000cited by this paper
• Differential regulation by troglitazone of plasminogen activator inhibitor type 1 in human hepatic and vascular cells.

  2000cited by this paper
• The role of strict metabolic control by insulin infusion on fibrinolytic profile during an acute coronary event in diabetic patients

  2000cited by this paper
• Vitamin E supplementation and cardiovascular events in high-risk patients.

  2000cited by this paper
• CAROTID-ARTERY INTIMA AND MEDIA THICKNESS AS A RISK FACTOR FOR MYOCARDIAL INFARCTION AND STROKE IN OLDER ADULTS

  2000cited by this paper
• Expression and function of PPARgamma in rat and human vascular smooth muscle cells.

  2000cited by this paper
• Hepatic Failure in a Patient Taking Rosiglitazone

  2000cited by this paper
• A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones.

  2000cited by this paper
• Hepatocellular Injury in a Patient Receiving Rosiglitazone: A Case Report

  2000cited by this paper
• Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

  2000cited by this paper
• PPARγ Activation in Human Endothelial Cells Increases Plasminogen Activator Inhibitor Type-1 Expression PPARγ as a Potential Mediator in Vascular Disease

  1999cited by this paper
• Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects.

  1999cited by this paper
• Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus.

  1999cited by this paper
• PPARγ, the ultimate thrifty gene

  1999cited by this paper
• Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARgamma on vascular endothelial function.

  1999influential reference
• Coronary Artery Disease and Fibrinolysis: From the Blood to the Vessel Wall

  1999cited by this paper
• PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease.

  1999cited by this paper
• PPARgamma, the ultimate thrifty gene.

  1999cited by this paper
• Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes.

  1999cited by this paper
• Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group.

  1999cited by this paper
• The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats.

  1999cited by this paper
• Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma.

  1998cited by this paper
• Two Cases of Severe Clinical and Histologic Hepatotoxicity Associated with Troglitazone

  1998cited by this paper
• Effect of Troglitazene on Microalbuminuria in Patients With Incipient Diabetic Nephropathy

  1998cited by this paper
• Troglitazone Reduces LDL Oxidation and Lowers Plasma E-selectin Concentration in NIDDM Patients

  1998cited by this paper
• Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome.

  1998cited by this paper
• PPAR-γ agonists inhibit production of monocyte inflammatory cytokines

  1998cited by this paper
• Mechanisms of vasorelaxation induced by troglitazone, a novel antidiabetic drug, in the porcine coronary artery.

  1998cited by this paper
• Human Trabecular Bone Cells Are Able to Express Both Osteoblastic and Adipocytic Phenotype: Implications for Osteopenic Disorders

  1998cited by this paper
• Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγ

  1998influential reference
• Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells.

  1998influential reference
• Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro.

  1998cited by this paper
• Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo.

  1998cited by this paper
• PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL

  1998cited by this paper
• PPARγ in Monocytes: Less Pain, Any Gain?

  1998cited by this paper
• Thiazolidinediones Inhibit Lipoprotein Lipase Activity in Adipocytes*

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

  1998cited by this paper
• Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus.

  1998influential reference
• PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL.

  1998cited by this paper
• Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone

  1998cited by this paper
• Differentiation and reversal of malignant changes in colon cancer through PPARγ

  1998cited by this paper
• Metabolic Effects of Troglitazone Monotherapy in Type 2 Diabetes Mellitus

  1998cited by this paper
• Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes.

  1998cited by this paper
• Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus.

  1998cited by this paper
• Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein

  1998cited by this paper
• Troglitazone Lowers Islet Fat and Restores Beta Cell Function of Zucker Diabetic Fatty Rats*

  1998cited by this paper
• Troglitazone Decreases the Proportion of Small, Dense LDL and Increases the Resistance of LDL to Oxidation in Obese Subjects

  1998cited by this paper
• Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes.

  1998cited by this paper
• PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines.

  1998cited by this paper
• PPARgamma in monocytes: less pain, any gain?

  1998cited by this paper
• Troglitazone-Induced Hepatic Failure Leading to Liver Transplantation: A Case Report

  1998cited by this paper
• Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice.

  1998cited by this paper
• Troglitazone, an insulin sensitizer, increases forearm blood flow in humans.

  1998cited by this paper
• Cardiovascular risk continuum: implications of insulin resistance and diabetes.

  1998cited by this paper
• Troglitazone Inhibits Progesterone Production in Porcine Granulosa Cells *

  1998cited by this paper
• Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro.

  1998cited by this paper
• Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism.

  1998cited by this paper
• Peroxisome Proliferator-Activated Receptor-γ Agonist, Rosiglitazone, Protects Against Nephropathy and Pancreatic Islet Abnormalities in Zucker Fatty Rats

  1998cited by this paper
• Macrophages in Human Atheroma Contain PPARγ: Differentiation-Dependent Peroxisomal Proliferator-Activated Receptor γ (PPARγ) Expression and Reduction of MMP-9 Activity through PPARγ Activation in Mononuclear Phagocytes in Vitro

  1998cited by this paper
• Troglitazone inhibits progesterone production in porcine granulosa cells.

  1998cited by this paper
• Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein.

  1998cited by this paper
• Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Troglitazone Improves Defects in Insulin Action , Insulin Secretion , Ovarian Steroidogenesis , and Fibrinolysis in Women with Polycystic Ovary Syndrome *

  1997influential reference
• Impaired Glucose Tolerance is Normalized by Treatment With the Thiazolidinedione Troglitazone

  1997cited by this paper
• Non-invasive assessment of cardiovascular disease in diabetes mellitus.

  1997influential reference
• The unstable atheroma.

  1997cited by this paper
• Troglitazone (CS-045) ameliorates albuminuria in streptozotocin-induced diabetic rats.

  1997cited by this paper
• The impact of cardiovascular disease on people with diabetes: the potential for prevention.

  1997cited by this paper
• Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome.

  1997cited by this paper
• Effects of troglitazone on in vitro oxidation of LDL and HDL induced by copper ions and endothelial cells

  1997cited by this paper
• Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance.

  1997cited by this paper
• Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation.

  1997cited by this paper
• Troglitazone ameliorates insulin resistance in patients with Werner's syndrome.

  1997cited by this paper
• Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 Glucose Clamp Study Group, Japan.

  1997cited by this paper
• Troglitazone increases the resistance of low density lipoprotein to oxidation in healthy volunteers

  1997cited by this paper
• Troglitazone Reduces Contraction by Inhibition of Vascular Smooth Muscle Cell Ca2+ Currents and Not Endothelial Nitric Oxide Production

  1997cited by this paper
• Cardiac and Glycemic Benefits of Troglitazone Treatment in NIDDM

  1997cited by this paper
• Hyperinsulinemia as an independent risk factor for ischemic heart disease.

  1996cited by this paper
• Inhibition of oxidation of low density lipoprotein by troglitazone.

  1996cited by this paper
• Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance.

  1996cited by this paper
• Thiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes

  1996cited by this paper
• Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia.

  1996cited by this paper
• Differential inhibitory effects of antidiabetic drugs on arterial smooth muscle cell proliferation.

  1996cited by this paper
• Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives.

  1995cited by this paper
• Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect.

  1995cited by this paper
• Pioglitazone attenuates diet-induced hypertension in rats.

  1995cited by this paper
• Clinical implications of insulin resistance syndromes.

  1995cited by this paper
• Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.

  1994cited by this paper
• Syndrome X: 6 years later.

  1994cited by this paper
• Effects of pioglitazone on calcium channels in vascular smooth muscle.

  1994cited by this paper
• Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release.

  1994cited by this paper
• Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B.

  1993cited by this paper
• Detection and Management of Lipid Disorders in Diabetes

  1993cited by this paper
• Effects of Metformin on Insulin Resistance, Risk Factors for Cardiovascular Disease, and Plasminogen Activator Inhibitor in NIDDM Subjects: A study of two ethnic groups

  1993cited by this paper
• Prospective Study of Microalbuminuria as Predictor of Mortality in NIDDM

  1992cited by this paper
• Metabolic Effects of New Oral Hypoglycemic Agent CS-045 in NIDDM Subjects

  1992cited by this paper

• Effect of Exercise Training on Peroxisome Proliferator-Activated Receptor γ (PPAR-γ) Level: A Systematic Review

  2023cites this paper
• Efficacy of 3 months of additional pioglitazone treatment in type 2 diabetes patients with alcoholic fatty liver disease

  2023cites this paper
• Molecular Docking Studies of Novel Thiazolidinedionederivatives as PPARγ Modulators

  2023cites this paper
• Peroxisome Proliferator-Activated Receptors as Superior Targets for Treating Diabetic Disease, Design Strategies - Review Article.

  2021cites this paper
• The role of PPARγ in chemotherapy-evoked pain.

  2021cites this paper
• Antidiabetic Flavonoids from Fruits of Morus alba Promoting Insulin-Stimulated Glucose Uptake via Akt and AMP-Activated Protein Kinase Activation in 3T3-L1 Adipocytes

  2021cites this paper
• PPARγ agonistic activity of sulphonylureas.

  2019cites this paper
• The scope of phytotherapy in southern African antidiabetic healthcare

  2019cites this paper
• The Journey of Thiazolidinediones as Modulators of PPARs for the Management of Diabetes: A Current Perspective.

  2019cites this paper
• Endothelial Cell–Targeted Deletion of PPARγ Blocks Rosiglitazone-Induced Plasma Volume Expansion and Vascular Remodeling in Adipose Tissue

  2019cites this paper
• BARI 2D: A Reanalysis Focusing on Cardiovascular Events.

  2019cites this paper
• Effect of PPARγ agonist on aerobic exercise capacity in relation to body fat distribution in men with type 2 diabetes mellitus and coronary artery disease: a 1-yr randomized study.

  2019cites this paper
• Development of a novel class of peroxisome proliferator-activated receptor (PPAR) gamma ligands as an anticancer agent with a unique binding mode based on a non-thiazolidinedione scaffold.

  2019cites this paper
• Protein Tyrosine Phosphatase 1B inhibitors: a novel therapeutic strategy for the management of type 2 diabetes mellitus.

  2019cites this paper
• Effect of pioglitazone on inflammation and calcification in atherosclerotic rabbits

  2018cites this paper
• Rosiglitazone lowers resting and blood pressure response to exercise in men with type 2 diabetes: A 1‐year randomized study

  2018cites this paper
• Development of Dihydrodibenzooxepine Peroxisome Proliferator-Activated Receptor (PPAR) Gamma Ligands of a Novel Binding Mode as Anticancer Agents: Effective Mimicry of Chiral Structures by Olefinic E/ Z-Isomers.

  2018cites this paper
• Efficacy and safety of pioglitazone plus phototherapy versus phototherapy in patients with plaque type psoriasis: a Double Blinded Randomized Controlled Trial

  2018cites this paper
• Antioxidative potential of antidiabetic agents: A possible protective mechanism against vascular complications in diabetic patients

  2018cites this paper
• Targeting Insulin for Alzheimer’s Disease: Mechanisms, Status and Potential Directions

  2018cites this paper
• Novel Benzylidene Thiazolidinedione Derivatives as Partial PPARγ Agonists and their Antidiabetic Effects on Type 2 Diabetes

  2017cites this paper
• Thiazolidinediones and PPAR orchestra as antidiabetic agents: From past to present.

  2017cites this paper
• Comparative Design, In Silico Dockingand Predictive ADME/ TOX Properties of Some Novel 2, 4-hydroxy Derivatives of Thiazolidine-2, 4-diones as PPARγ Modulator

  2017cites this paper
• An ErChen and YinChen Decoction Ameliorates High-Fat-Induced Nonalcoholic Steatohepatitis in Rats by Regulating JNK1 Signaling Pathway

  2017cites this paper
• Cardiovascular safety of type 2 diabetes medications: Review of existing literature and clinical implications

  2016cites this paper
• Effects of nateglinide and rosiglitazone on pancreatic alpha- and beta-cells, GLP-1 secretion and inflammatory markers in patients with type 2 diabetes: randomized crossover clinical study

  2016cites this paper
• Effects of a combination of puerarin, baicalin and berberine on the expression of proliferator-activated receptor-γ and insulin receptor in a rat model of nonalcoholic fatty liver disease.

  2016cites this paper
• REVISITING THE USE OF PIOGLITAZONE IN THE TREATMENT OF TYPE 2 DIABETES.

  2016cites this paper
• Management of Cardiovascular Risk Factors in Type 2 Diabetes Mellitus Patients

  2016cites this paper
• Continuation or discontinuation of pioglitazone when starting bedtime insulin in patients with poorly controlled type 2 diabetes in an inner-city population.

  2015cites this paper
• The efficacy of methotrexate plus pioglitazone vs. methotrexate alone in the management of patients with plaque‐type psoriasis: a single‐blinded randomized controlled trial

  2015cites this paper
• Effect of Rosiglitazone and Insulin Combination Therapy on Inflammation Parameters and Adipocytokine Levels in Patients with Type 1 DM

  2015cites this paper
• Clinical Feasibility and Monitoring of the Effects of Anti-inflammatory Therapy in Atherosclerosis

  2015cites this paper
• PPARγ partial agonist GQ-16 strongly represses a subset of genes in 3T3-L1 adipocytes.

  2015cites this paper
• Oral anti-diabetic agents-review and updates.

  2015cites this paper
• Oral antihyperglycemic treatment options for type 2 diabetes mellitus.

  2015cites this paper
• The Comparative Effect of Pioglitazone and Metformin on Serum Osteoprotegerin, Adiponectin and Intercellular Adhesion Molecule Concentrations in Patients with Newly Diagnosed Type 2 Diabetes: a Randomized Clinical Trial

  2015cites this paper
• Fucosylated chondroitin sulfate from sea cucumber improves insulin sensitivity via activation of PI3K/PKB pathway.

  2014cites this paper
• Effects of pioglitazone on blood glucose and inflammatory markers of diabetic kidney transplant patients: a randomized controlled trial.

  2014cites this paper
• PPARγ Agonist-Induced Fluid Retention Depends on αENaC Expression in Connecting Tubules

  2014cites this paper
• Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?

  2014cites this paper
• Combined effect of C occinia indica leaf extract with acarbose in type II diabetes induced neuropathy in rats

  2014cites this paper
• Impact of hypoglycemic agents on myocardial ischemic preconditioning.

  2014cites this paper
• Adipokines in Nonalcoholic Fatty Liver Disease

  2014cites this paper
• Effect of Taurine on The Respiratory System of Rats

  2013cites this paper
• Comparison between the efficacies of curcumin and puerarin in C57BL/6 mice with steatohepatitis induced by a methionine- and choline-deficient diet

  2013cites this paper
• Koroner kalp hastaliğinda peroksizom proliferatör-aktive reseptör (PPAR) izoformlari

  2013cites this paper
• Peroxisome proliferator-activated receptor (PPAR) isoforms in coronary heart disease

  2013cites this paper
• Expansion: Role of Dysregulation of Renal Water Transporters

  2013cites this paper
• High-Density Lipoprotein as a Therapeutic Target: Treatment Strategies

  2012cites this paper
• Synthesis, characterization, biological evaluation and docking of coumarin coupled thiazolidinedione derivatives and its bioisosteres as PPARγ agonists.

  2012cites this paper
• Reversible mitral and aortic regurgitation due to pioglitazone.

  2012cites this paper
• Pharmacodynamic Interaction of Fenugreek Seeds Extract with Fluvastatin in Diabetes Induced Vascular Dysfunction

  2012cites this paper
• Effects of rosiglitazone on the cardiovascular profile in postmenopausal women without diabetes mellitus: interplay of thiazolidinediones and hormone therapy

  2012cites this paper
• Oral Antidiabetic Agents

  2012cites this paper
• Diabetes and Coronary Heart Disease

  2012cites this paper
• Improvement of abnormal liver enzymes after rosiglitazone treatment in Chinese type 2 diabetes

  2012cites this paper
• New Solutions for Type 2 Diabetes Mellitus

  2012cites this paper
• Clinical project management: dalla progettazione al monitoraggio di un trial clinico.

  2012cites this paper
• Insulin resistance: Is it time for primary prevention?

  2012cites this paper
• Thiazolidinediones in Type 2 Diabetes Mellitus

  2012cites this paper
• Synthesis, glucose uptake activity and structure-activity relationships of some novel glitazones incorporated with glycine, aromatic and alicyclic amine moieties via two carbon acyl linker.

  2011cites this paper
• Thiazolidinedione use in elderly patients with type 2 diabetes: with and without heart failure

  2011cites this paper
• Visceral adipose tissue accumulation and cardiovascular disease risk profile in postmenopausal women with impaired glucose tolerance or type 2 diabetes

  2011cites this paper
• Thiazolidinediones and congestive heart failure in veterans with type 2 diabetes

  2011cites this paper
• Preserved Response to Diuretics in Rosiglitazone‐Treated Subjects With Insulin Resistance: A Randomized Double‐Blind Placebo‐Controlled Crossover Study

  2011cites this paper
• Peroxisome Proliferator-Activated Receptor-Gamma Agonists Suppress Tissue Factor Overexpression in Rat Balloon Injury Model with Paclitaxel Infusion

  2011cites this paper
• Rosiglitazone decreases bone mass and bone marrow fat.

  2011cites this paper
• The pluripotential effects of hypolipidemic treatment for polycystic ovary syndrome (PCOS): dyslipidemia, cardiovascular risk factors and beyond.

  2011cites this paper
• Oral Agents for Type-2 Diabetes

  2011cites this paper
• Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta.

  2011cites this paper
• Anti-Diabetic Actions of a Non-Agonist PPARγ Ligand Blocking Cdk5-Mediated Phosphorylation

  2011cites this paper
• Plaque Passivation and Endothelial Therapy

  2011cites this paper
• Genetic Deletion or Pharmacological Inhibition of Dipeptidyl Peptidase-4 Improves Cardiovascular Outcomes After Myocardial Infarction in Mice

  2010cites this paper
• The role of insulin resistance in the pathogenesis of atherosclerotic cardiovascular disease: an updated review

  2010cites this paper
• Insulin-sensitizing agents in the treatment of polycystic ovary syndrome: an update

  2010cites this paper
• Exercise training ameliorates the effects of rosiglitazone on traditional and novel cardiovascular risk factors in patients with type 2 diabetes mellitus.

  2010cites this paper
• High-density lipoprotein and coronary heart disease: current and future therapies.

  2010cites this paper
• Rosiglitazone reduces plasma levels of inflammatory and hemostatic biomarkers and improves global endothelial function in habitual heavy smokers without diabetes mellitus or metabolic syndrome.

  2010cites this paper
• Relationship between urinary sodium excretion and pioglitazone‐induced edema

  2010cites this paper
• METABOLIC AND HORMONAL STUDIES IN SOUTH AFRICAN WOMEN OF INDIAN AND AFRICAN ORIGIN

  2010cites this paper
• Nonalcoholic Fatty Liver Disease

  2010cites this paper
• Pioglitazone induces regression of coronary atherosclerotic plaques in patients with type 2 diabetes mellitus or impaired glucose tolerance: a randomized prospective study using intravascular ultrasound.

  2010cites this paper
• Does Choice of Antidiabetes Therapy Influence Macrovascular Outcomes?

  2010cites this paper
• Autonomic neuropathy predisposes to rosiglitazone-induced vascular leakage in insulin-treated patients with type 2 diabetes: a randomised, controlled trial on thiazolidinedione-induced vascular leakage

  2010cites this paper
• 3beta-taraxerol of Mangifera indica, a PI3K dependent dual activator of glucose transport and glycogen synthesis in 3T3-L1 adipocytes.

  2010cites this paper
• Psoriasis: what is new in nonbiologic systemic therapy in the era of biologics?

  2010cites this paper
• Impact of glitazones on metabolic and haemodynamic parameters in patients with type 2 diabetes mellitus.

  2009cites this paper
• 50 Metabolic Syndrome : Assessing Cardiometabolic Risk

  2009cites this paper
• Efficacy and safety of combination Acitretin and Pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, double-blind, placebo-controlled clinical trial.

  2009cites this paper
• Animal models of catheter-induced intimal hyperplasia in type 1 and type 2 diabetes and the effects of pharmacologic intervention.

  2009cites this paper
• Insulin Sensitizers and Cardiovascular Disease

  2009cites this paper
• Pan-PPAR agonist beneficial effects in overweight mice fed a high-fat high-sucrose diet.

  2009cites this paper
• The PPAR‐γ agonist rosiglitazone facilitates Akt rephosphorylation and inhibits apoptosis in cardiomyocytes during hypoxia/reoxygenation

  2009cites this paper
• Title Current understanding of the role of PPAR γ in gastrointestinalcancers

  2009cites this paper
• Potential of glucose-lowering drugs to reduce cardiovascular events

  2009cites this paper
• Thiazolidinedione-induced fluid retention is independent of collecting duct alphaENaC activity.

  2009cites this paper
• Endemic Fungal Infections in Patients Receiving Tumour Necrosis Factor-α Inhibitor Therapy

  2009cites this paper
• Current Understanding of the Role of PPARγ in Gastrointestinal Cancers

  2009cites this paper
• Medical Antihyperglycaemic Treatment of Type 2 Diabetes Mellitus*

  2009cites this paper